Prevention of transient endothelial dysfunction in acute exercise: A friendly fire?

• References

• 1 Kojda G, Hambrecht R. Molecular mechanisms of vascular adaptations to exercise. Physical activity as an effective antioxidant therapy?. Cardiovasc Res 2005; 67: 187-197.
• 2 Hambrecht R. et al. Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease: a randomized trial. Circulation 2004; 109: 1371-1378.
• 3 Green DJ. et al. Effect of exercise training on endothelium- derived nitric oxide function in humans. J Physiol 2004; 561: 1-25.
• 4 Laurindo FRM. et al. Vascular free radical release: Ex vivo and in vivo evidence for a flow-dependent endothelial mechanism. Circ Res 1994; 74: 700-709.
• 5 Suvorava T. et al. Endogenous vascular hydrogen peroxide regulates arteriolar tension in vivo. Circulation 2005; 112: 2487-2495.
• 6 Lauer N. et al. Critical Involvement of Hydrogen Peroxide In Exercise-Induced Upregulation Of Endothelial NO-Synthase. Cardiovasc Res 2005; 65: 254-262.
• 7 Fukai T. et al. Regulation of the vascular extracellular superoxide dismutase by nitric oxide and exercise training. J Clin Invest 2000; 105: 1631-1639.
• 8 Richardson RS. et al. Exercise-induced brachial artery vasodilation: The role of free radicals. Am J Physiol Heart Circ Physiol. 2006 epub ahead of print
• 9 Gresele P. et al. Prevention by NCX 4016, a nitric oxide-donating aspirin, but not by aspirin, of the acute endothelial dysfunction induced by exercise in patients with intermittent claudication. Thromb Haemost 2007; 97: 444-450.
• 10 Bode-Boger SM, Kojda G. Organic nitrates in cardiovascular disease. Cell Mol Biol (Noisy -le-grand) 2005; 51: 307-320.
• 11 Gao J. et al. In vitro metabolism of nitric oxide-donating aspirin: the effect of positional isomerism. J Pharmacol Exp Ther 2005; 312: 989-997.
• 12 Gewaltig MT, Kojda G. Vasoprotection by nitric oxide: mechanisms and therapeutic potential. Cardiovasc Res 2002; 55: 250-260.
• 13 Bolla M. et al. Nitric oxide-donating aspirin (NCX 4016): an overview of its pharmacological properties and clinical perspectives. Eur J Clin Pharmacol 2006; 62 (Suppl. 01) (Suppl) 145-154.
• 14 Nath N. et al. Nitric oxide-donating aspirin inhibits beta-catenin/T cell factor (TCF) signaling in SW480 colon cancer cells by disrupting the nuclear beta-catenin- TCF association. Proc Natl Acad Sci USA 2003; 100: 12584-12589.
• 15 Rao CV. et al. Nitric oxide-releasing aspirin and indomethacin are potent inhibitors against colon cancer in azoxymethane-treated rats: effects on molecular targets. Mol Cancer Ther 2006; 5: 1530-1538.
• 16 Kojda G. Direct vasoprotection by aspirin: a significant bonus to antiplatelet activity?. Cardiovasc Res 2004; 64: 192-194.